Solid Solution Lipid Adjuvant Delivery for Chronic Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammation are limited due to the complexity of the inflammatory response and the redundancy of mechanisms involved, with many anti-inflammatory drugs inhibiting both pro-inflammatory and anti-inflammatory molecules, leading to incomplete or prolonged inflammation.
Innovation Solution
Development of solid solution pharmaceutical compositions that utilize a lipid-adjuvant delivery system to selectively inhibit pro-inflammatory responses, allowing for targeted delivery of therapeutic compounds to sites of inflammation, such as macrophages and dendritic cells, using a combination of room temperature solid and liquid lipids, stabilizing agents, and neutralizing agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory drugs are used to treat chronic inflammation, then inflammation symptoms are reduced, but both pro-inflammatory and anti-inflammatory molecules are inhibited leading to incomplete or prolonged inflammation resolution
Solution Approach 1:
The solid solution composition delivers the therapeutic compound specifically to inflamed tissues through lipid-adjuvant mechanisms, creating localized high concentration at the target site while maintaining selective inhibition of pro-inflammatory pathways. This localized delivery ensures complete inflammation resolution without systemic suppression of anti-inflammatory molecules.
Solution Approach 2:
The invention changes the physical state of the therapeutic compound by formulating it as a solid solution within a lipid matrix, altering its solubility, stability, and cellular uptake characteristics. This parameter change enables selective accumulation in macrophages and dendritic cells at inflamed sites, achieving preferential inhibition of pro-inflammatory responses without affecting systemic anti-inflammatory pathways.
2Object-affected harmful factors
If non-selective anti-inflammatory drugs are used, then general inflammation is reduced, but side effects increase due to inhibition of protective anti-inflammatory mechanisms
Solution Approach 1:
The solid solution composition creates localized high concentration of the therapeutic compound specifically at inflamed tissues through lipid-adjuvant delivery. This local concentration effect provides potent anti-inflammatory action at the target site while avoiding systemic suppression of protective anti-inflammatory mechanisms, thereby reducing side effects.
Solution Approach 2:
The lipid matrix acts as an intermediary carrier that facilitates selective delivery of the therapeutic compound to inflamed tissues. The lipid-adjuvant system mediates between the drug and target cells, enabling preferential accumulation in macrophages and dendritic cells while sparing normal tissues from drug exposure and associated side effects.
3Adaptability or versatility
If therapeutic compounds are delivered systemically, then widespread inflammation is addressed, but targeted delivery to specific inflammatory sites is reduced
Solution Approach 1:
The solid solution composition inherently directs the therapeutic compound to inflamed tissues through the lipid-adjuvant mechanism, creating automatic targeting based on the inflammatory state. This local quality approach simultaneously achieves widespread coverage of all inflamed sites while maintaining high targeted delivery accuracy without requiring systemic distribution.
Solution Approach 2:
The lipid matrix in the solid solution composition self-directs the therapeutic compound to inflamed tissues through natural lipid metabolism pathways and cellular uptake mechanisms. The system serves itself by utilizing the inflammatory environment to guide drug accumulation in macrophages and dendritic cells at affected sites, achieving both broad coverage and precise targeting without external intervention.
Data Source
AI summary
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.